Table 1.

Effect of chronic Δ9-THC treatment on basal and WIN 55212-2-stimulated [35S]GTPγS binding in the rat brain

RegionBasalStimulated
ControlChronic Δ9-THCControlChronic Δ9-THC
Hippocampus (D)100  ± 6%92  ± 4%181  ± 9%125  ± 7%
Hippocampus (M)100  ± 8%101  ± 6%188  ± 11%132  ± 10%
Hippocampus (V)100  ± 7%99  ± 4%196  ± 13%129  ± 8%
Perirhinal cortex (M)100  ± 6%94  ± 3%178  ± 11%127  ± 6%*
Perirhinal cortex (V)100  ± 10%83  ± 2%166  ± 10%117  ± 6%
Entorhinal cortex (D)100  ± 5%96  ± 8%156  ± 7%133  ± 7%*
Entorhinal cortex (M)100  ± 6%100  ± 2%174  ± 9%132  ± 3%
Entorhinal cortex (V)100  ± 10%108  ± 4%189  ± 14%144  ± 5%*
Septum100  ± 7%104  ± 6%157  ± 12%144  ± 2%
Caudate-putamen (D)100  ± 6%81  ± 9%191  ± 14%134  ± 4%
Caudate-putamen (M)100  ± 5%85  ± 2%*163  ± 12%118  ± 7%
Globus pallidus100  ± 8%73  ± 4%*362  ± 18%206  ± 19%
Substantia nigra100  ± 6%85  ± 8%484  ± 12%349  ± 11%
Cerebellum100  ± 5%123  ± 4%*185  ± 13%167  ± 12%
PAG100  ± 8%92  ± 10%122  ± 4%114  ± 9%
  • Sections were incubated with 2 mm GDP, and then with [35S]GTPγS (0.04 nm) and 2 mmGDP, with and without 10 μm WIN 55212-2. Data are expressed as percentage of control basal binding and represent mean values ± SE of duplicate sections from five animals. The level of the sections measured are dorsal (D), Figure 2 (top); midlevel (M), Figure2 (middle); and ventral (V), Figure 2 (bottom).

  • * p < 0.05;

  • p < 0.01;

  • p < 0.005.